Table 1.
Clinical trials of ivermectin (from ClinicalTrials.gov and CTRI as of 16-10-2020)
| Trial registration | Phase/status | Intervention/comparator | Study design | Size/location | |
|---|---|---|---|---|---|
| 1 | NCT04343092 |
Phase 1 Completed |
Ivermectin |
Randomized, parallel Masking: double |
100 Iraq |
| 2 | NCT04422561 |
Phase 2/phase 3 Completed |
Ivermectin |
Randomized, sequential Masking: none |
340 Egypt |
| 3 | NCT04434144 | Completed |
Ivermectin + doxycycline Hydroxychloroquine + azithromycin |
Prospective, case-only |
116 Bangladesh |
| 4 | NCT04381884 |
Phase 2 Completed |
Ivermectin plus standard care Control arm will receive standard care |
Randomized, parallel Masking: none |
45 Argentina |
| 5 | NCT04446104 |
Phase 3 Completed |
Hydroxychloroquine sulfate tablets Ivermectin 3 Mg Tab Zinc Povidone-iodine Supplement: vitamin C |
Randomized, parallel Masking: none |
4257 Singapore |
| 6 | NCT04523831 |
Phase 3 Completed |
Ivermectin and doxycycline Standard of care |
Randomized, parallel Masking: double |
400 Bangladesh |
| 7 | NCT04438850 |
Phase 2 Recruiting |
Ivermectin Placebo |
Randomized, sequential Masking: quadruple |
102 Italy |
| 8 | NCT04425707 |
Not applicable Recruiting |
Ivermectin |
Randomized, parallel Masking: none |
100 Egypt |
| 9 | NCT04429711 |
Not applicable Recruiting |
Ivermectin oral product |
Randomized, parallel Masking: quadruple |
100 Israel |
| 10 | NCT04405843 |
Phase 2| Phase 3 Recruiting |
Ivermectin oral product Placebo |
Randomized, parallel Masking: quadruple |
400 Colombia |
| 11 | NCT04445311 |
Phase 2|Phase 3 Recruiting |
Ivermectin |
Randomized, parallel Masking: none |
100 Egypt |
| 12 | NCT04392713 |
Not applicable Recruiting |
Ivermectin 6 MG oral tablet (2 tablets) |
Randomized, parallel Masking: none |
100 Pakistan |
| 13 | NCT04351347 |
Phase 2|Phase 3 Recruiting |
Ivermectin Nitazoxanide with ivermectin Ivermectin wth chloroquine |
Randomized, parallel Masking: none |
300 Egypt |
| 14 | NCT04431466 |
Phase 2 Recruiting |
Ivermectin Standard treatment for COVID-19 |
Randomized, parallel Masking: triple |
64 Brazil |
| 15 | NCT04529525 |
Phase 2|Phase 3 Recruiting |
Ivermectin Placebo |
Randomized, parallel Masking: quadruple |
500 Colombia |
| 16 | NCT04384458 |
Not applicable Recruiting |
Hydroxychloroquine Ivermectin |
Randomized, parallel Masking: none |
400 Brazil |
| 17 | NCT04373824 |
Not applicable Recruiting |
Ivermectin |
Non-randomized, crossover Masking: None |
50 India |
| 18 | NCT04403555 |
Phase 2|Phase 3 Recruiting |
Ivermectin Doxycycline Chloroquine |
Randomized, parallel Masking: None |
200 Egypt |
| 19 | NCT04447235 |
Phase 2 Recruiting |
Placebo Ivermectin Losartan |
Randomized, parallel Masking: double |
176 Brazil |
| 20 | NCT04472585 |
Phase 1|Phase 2 Recruiting |
Nigella sativa/black cumin Ivermectin injectable solution Placebo Zinc |
Randomized, parallel Masking: quadruple |
40 Pakistan |
| 21 | NCT04399746 |
Not applicable Recruiting |
Ivermectin Azithromycin Cholecalciferol |
Non-randomized, parallel Masking: none |
30 Mexico |
| 22 | NCT04374019 |
Phase 2 Recruiting |
Hydroxychloroquine and azithromycin Ivermectin Camostat mesilate Artemesia annua |
Randomized, parallel Masking: none |
240 US |
| 23 | NCT04391127 |
Phase 3 Active, not recruiting |
Hydroxychloroquine Ivermectin Placebo |
Randomized, parallel Masking: double |
108 Mexico |
| 24 | NCT04390022 |
Phase 2 Active, not recruiting |
Ivermectin Placebo |
Randomized, parallel Masking: double |
24 Spain |
| 25 | NCT04425863 | Active, not recruiting | Ivermectin 5 mg/mL | Prospective, cohort |
100 Argentina |
| 26 | NCT04425850 | Active, not recruiting |
Iota carrageenan Ivermectin |
Prospective, cohort |
70 Argentina |
| 27 | NCT04407130 |
Phase 2 Enrolling by invitation |
Ivermectin + doxycycline + placebo Ivermectin + placebo Placebo |
Randomized, parallel Masking: double |
72 Bangladesh |
| 28 | NCT04510233 |
Phase 2 Not yet recruiting |
Ivermectin nasal Ivermectin oral Standard care |
Randomized, parallel Masking: none |
60 |
| 29 | NCT04360356 |
Phase 2| Phase 3 Not yet recruiting |
Ivermectin plus Nitazoxanide Standard Care |
Randomized, parallel Masking: double |
100 |
| 30 | NCT04407507 |
Phase 2 Not yet recruiting |
Ivermectin Placebo |
Randomized, parallel Masking: single |
66 |
| 31 | NCT04392427 |
Phase 3 Not yet recruiting |
Nitazoxanide, ribavirin and ivermectin for 7 days |
Randomized, sequential Masking: single |
100 Egypt |
| 32 | NCT04435587 |
Phase 4 Not yet recruiting |
Ivermectin pill Combined ART/hydroxychloroquine |
Randomized, parallel Masking: single |
80 Thailand |
| 33 | NCT04382846 |
Phase 3 Not yet recruiting |
Nitazoxanide Ivermectin Chloroquine Azithromycin |
Randomized, parallel Masking: none |
80 |
| 34 | NCT04460547 | Not yet recruiting |
Convalescent plasma transfusion Hydroxychloroquine DAS181 Ivermectin Interferon beta-1A |
Retrospective, cohort | 200 |
| 35 | NCT04482686 |
Phase 2 Not yet recruiting |
Ivermectin Doxycycline Hcl Zinc Vitamin D3 Vitamin C |
Randomized, parallel Masking: triple |
300 US |
| 36 | NCT04551755 |
Phase 2 Not yet recruiting |
Ivermectin and doxycycline Placebo |
Randomized, parallel Masking: triple |
188 |
| 37 | NCT04530474 |
Phase 3 Not yet recruiting |
Ivermectin pill Placebo |
Randomized, parallel Masking: triple |
200 US |
| 38 | NCT04527211 |
Phase 3 Not yet recruiting |
Ivermectin |
Randomized, parallel Masking: quadruple |
550 Argentina |
| 39 | CTRI/2020/04/024858 | Not yet recruiting |
Ivermectin (200–400 mcg/kg on day 1 and 2 in addition to standard treatment) Standard treatment |
Non-randomized, active controlled |
50 New Delhi, India |
| 40 | CTRI/2020/04/024948 |
Phase 2 Not yet recruiting |
Ciclesonide (200 mcg twice a day for 7 days) Hydroxychloroquine (400 mg twice a day, Day1 followed by 200 mg twice a day on Days 2–7) Ivermectin (12 mg once a day for 7 days) Standard of care |
Randomized, parallel |
120 New Delhi, India |
| 41 | CTRI/2020/05/025224 |
Phase 2 Not yet recruiting |
Ivermectin (12 mg once a day at night, oral for 2 days with standard of care) Standard of care |
Randomized, parallel |
50 Madhya Pradesh, India |
| 42 | CTRI/2020/06/025960 | Not yet recruiting |
Ivermectin (12 mg, per orally, once a day for 3 days) Standard of care |
Randomized, parallel, active controlled |
100 Maharashtra, India |
| 43 | CTRI/2020/06/026232 |
Phase 3 Not yet recruiting |
Ivermectin (single oral dose of 200 mcg/kg) | Single arm |
50 Andhra Pradesh, India |
| 44 | CTRI/2020/08/027225 | Not yet recruiting |
Ivermectin (12 mg orally on days 1 and 2) Placebo tablets |
Randomized, parallel, placebo controlled |
90 Bihar, India |
| 45 | CTRI/2020/08/027282 |
Phase 3 Not yet recruiting |
Ivermectin 12 mg or 36 mg one dose orally one time a day (two intervention arms) Two multivitamin tablets |
Randomized, parallel, multiple arm |
180 Uttar Pradesh, India |
| 46 | CTRI/2020/09/027944 |
Phase 3 Not yet recruiting |
Cefixime 200 mg (BD, 5 days), Ivermectin 12 mg (OD, day 1), Montelukast 10 mg (OD, 5 days), Ascoril LS 5 ml (TID, 5 days) Cefixime 200 mg, vitamin C, MVBC, antacids |
Randomized, parallel group, active controlled |
30 Maharashtra, India |